Literature DB >> 15812815

Schwann cells express erythropoietin receptor and represent a major target for Epo in peripheral nerve injury.

Xiaoqing Li1, Steven L Gonias, W Marie Campana.   

Abstract

Erythropoietin (Epo) expresses potent neuroprotective activity in the peripheral nervous system; however, the underlying mechanism remains incompletely understood. In this study, we demonstrate that Epo is upregulated in sciatic nerve after chronic constriction injury (CCI) and crush injury in rats, largely due to local Schwann cell production. In uninjured and injured nerves, Schwann cells also express Epo receptor (EpoR), and its expression is increased during Wallerian degeneration. CCI increased the number of Schwann cells at the injury site and the number was further increased by exogenously administered recombinant human Epo (rhEpo). To explore the activity of Epo in Schwann cells, primary cultures were established. These cells expressed cell-surface Epo receptors, with masses of 71 and 62 kDa, as determined by surface protein biotinylation and affinity precipitation. The 71-kDa species was rapidly but transiently tyrosine-phosphorylated in response to rhEpo. ERK/MAP kinase was also activated in rhEpo-treated Schwann cells; this response was blocked by pharmacologic antagonism of JAK-2. RhEpo promoted Schwann cell proliferation, as determined by BrdU incorporation. Cell proliferation was ERK/MAP kinase-dependent. These results support a model in which Schwann cells are a major target for Epo in injured peripheral nerves, perhaps within the context of an autocrine signaling pathway. EpoR-induced cell signaling and Schwann cell proliferation may protect injured peripheral nerves and promote regeneration. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15812815     DOI: 10.1002/glia.20202

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  29 in total

1.  Therapeutic strategies for the inherited neuropathies.

Authors:  Michael E Shy
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 2.  Schwann cells as a therapeutic target for peripheral neuropathies.

Authors:  Helmar C Lehmann; Ahmet Höke
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-12       Impact factor: 4.388

3.  Use of Erythropoietin as adjuvant therapy in nerve reconstruction.

Authors:  J A Lohmeyer; E Essmann; S J Richerson; C Hagel; J T Egana; A Condurache; P Ganske; K Schulz; P Mailänder; H G Machens
Journal:  Langenbecks Arch Surg       Date:  2008-02-26       Impact factor: 3.445

4.  AlphaB-crystallin regulates remyelination after peripheral nerve injury.

Authors:  Erin-Mai F Lim; Stan T Nakanishi; Vahid Hoghooghi; Shane E A Eaton; Alexandra L Palmer; Ariana Frederick; Jo A Stratton; Morgan G Stykel; Patrick J Whelan; Douglas W Zochodne; Jeffrey Biernaskie; Shalina S Ousman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

5.  The unfolded protein response is a major mechanism by which LRP1 regulates Schwann cell survival after injury.

Authors:  Elisabetta Mantuano; Kenneth Henry; Tomonori Yamauchi; Nobuhiko Hiramatsu; Kazuyo Yamauchi; Sumihisa Orita; Kazuhisa Takahashi; Jonathan H Lin; Steven L Gonias; W Marie Campana
Journal:  J Neurosci       Date:  2011-09-21       Impact factor: 6.167

6.  Pharmacological Attenuation of Electrical Effects in a Model of Compression Neuropathy.

Authors:  Maxwell Modrak; Leigh Sundem; Ranjan Gupta; Michael J Zuscik; John Elfar
Journal:  J Bone Joint Surg Am       Date:  2019-03-20       Impact factor: 5.284

Review 7.  Molecules involved in the crosstalk between immune- and peripheral nerve Schwann cells.

Authors:  Nevena Tzekova; André Heinen; Patrick Küry
Journal:  J Clin Immunol       Date:  2014-04-17       Impact factor: 8.317

8.  The hemopexin domain of matrix metalloproteinase-9 activates cell signaling and promotes migration of schwann cells by binding to low-density lipoprotein receptor-related protein.

Authors:  Elisabetta Mantuano; Gen Inoue; Xiaoqing Li; Kazuhisa Takahashi; Alban Gaultier; Steven L Gonias; W Marie Campana
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

9.  Erythropoietin accelerates functional recovery after peripheral nerve injury.

Authors:  John C Elfar; Justin A Jacobson; J Edward Puzas; Randy N Rosier; Michael J Zuscik
Journal:  J Bone Joint Surg Am       Date:  2008-08       Impact factor: 5.284

10.  Erythropoietin: a multimodal neuroprotective agent.

Authors:  Nadiya Byts; Anna-Leena Sirén
Journal:  Exp Transl Stroke Med       Date:  2009-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.